Questcor Pharmaceuticals — Investor Presentation (June 2011)
27 slides from Questcor Pharmaceuticals's investor presentation, Jun 7, 2011
Slide 1: Questcor June 2011
NASDAQ: QCOR June 2011 Exhibit 99.1 NASDAQ: QCOR June 2011
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Note: Except for the historical information contained herein, this presentation contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performan
Slide 3: Questcor: a biopharmaceutical company for serious, difficult-to-treat conditions
3 Questcor A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions
Slide 4: Questcor Overview
4 Questcor Overview Flagship Product: • Profitable, cash flow positive, $133M* in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Combined market opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market • De
Slide 5: History of Acthar
5 History of Acthar 2000 2010 1950 1952 First Approved 1978 MS Indication Added 2000 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy 2010 1950
Slide 6: Significant Barriers to Entry
6 Significant Barriers to Entry
Slide 7: QCOR Strategy – Sell More Acthar
7 QCOR Strategy – Sell More Acthar Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) To Be Announced in July 2011
Slide 8: Acthar and MS
8 Acthar and MS Acthar when “Steroids are not suitable” *Based on prescriptions written • Neurodegenerative disorder • Acute treatment for relapses • Treatment for 1-2 weeks* • $40K-$50K/Rx Acthar when “Steroids are not suitable”
Slide 9: Multiple Sclerosis Potential Market
9 Multiple Sclerosis All numbers based on internal company estimates. US only. $500M to $2B+ Potential Market $500M to $2B+ $500M to $2B+ Potential Market Potential Market
Slide 10: MS Sales – Record of Consistent Growth
10 MS Sales – Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which
Slide 11: Strong Correlation – Sales Calls vs. Rxs
11 Strong Correlation-Sales Calls vs. Rxs *MS call data approximate
Slide 12: MS Trends
12 • Doubled sales force: 38 to 77 sales reps Nov 2010 • Q1-2011 results – Q1-11 new paid Rxs up 120% vs. Q1-10 – MS accounts for well over 50% of QCOR net sales • Estimated $75M annualized run-rate – February set new MS Rx record – March up 51% over February • Q2-2011 trends remain strong – Q1 mome
Slide 13: Acthar and Nephrotic Syndrome (NS)
13 • Characterized by excessive spilling of protein from the kidney into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options • Treatment for 4-6 months* • $150K-250K/Rx Acthar and Nephrotic Syndrome (NS) *Based
Slide 14: Estimated total: 20,000-25,000 patients
Estimated total: 20,000-25,000 patients (QQUESTCOR”
Slide 15: NS Sales
15 • Hired 5 reps to sell Acthar to nephrologists – Initiated sales efforts in early March 2011 – Q1 2011 NS Scripts: 18 • 14 different prescribers – Q1 momentum continuing into Q2 • Extended course of therapy results in growing future vial demand as new Rxs ramp up • Expanding the NS selling effort
Slide 16: NS R&D Plans
16 • Case series published in peer-reviewed journal – March 2011 • Other investigator initiated studies nearing completion – Anticipate data to be presented at ASN, November 2011 – Anticipate peer-reviewed publications in 2012 • Company sponsored dose response trial for idiopathic membranous nephrop
Slide 17: Infantile Spasms
17 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by
Slide 18: Acthar and IS
18 • FDA approval 10/15/10 – 7 year orphan exclusivity for IS indication • Crisis therapy • Treatment for 2-4 weeks* • In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks versus 29% on prednisone • $100K-$125K/Rx
Slide 19: IS Sales
19 • Targeting select institutions • Significant variability in quarterly prescriptions • Q1-2011 sales within historic range – Acthar currently used to treat 40-50% of IS patients IS Sales • Targeting select institutions • Significant variability in quarterly prescriptions • Q1-2011 sales within hi
Slide 20: Immediate Acthar Growth Opportunities
20 Immediate Acthar Growth Opportunities *Represents estimated net sales market opportunity based on internal company estimates ** Represents approximately 4 times Q1 11 net sales by therapeutic area based on internal company estimates
Slide 21: Financials
21 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive
Slide 22: Q1-2011 Financial Results
22 Q1-2011 Financial Results Record Sales (up 40%) and Solid Earnings (EPS up 42%) Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 36.8 95% $16.4 $0.17 $26.2 92% $12.0 $0.12 Q1-2011 Q1-2010 Record Sales (up 40%) and Solid Earnings (EPS up 42%) • First quarter vials shippe
Slide 23: Questcor is Cash Flow Positive
23 Questcor is Cash Flow Positive Debt-free balance sheet Cash / ST Investments Accounts Receivable $133M* $20M 5/24/11 *After return of $78 million of cash to shareholders through share repurchases. Debt-free balance sheet Cash / ST Investments Accounts Receivable $133M* $20M 5/24/11
Slide 24: Share Repurchases
24 Share Repurchases: 15 Million Shares • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 61.7 million shares currently outstanding • 4.3 million shares remain on buyback authorization Repurchases significantly improve EPS •
Slide 25: Go Forward Plan - Sell More Acthar
25 • Sustain effort and momentum with MS • Expand NS selling effort • Maintain and gradually grow IS sales • Develop other markets for Acthar – Acthar is its own pipeline with 15 other on-label and many possible other therapeutic uses – Announce next vertical market in July – Further define and deve
Slide 26: Questcor is streamlined, focused & profitable
Quesicor is streamlined, focused & profitable Acthar has sustainable com petitive advantages j Focus on substantial growth in MS and NS sales 20101S approval/label modernization Market sizes have good growth potential Cash flow positive/no debt (& QUESTCOR”
Slide 27: June 2011
NASDAQ: QCOR June 2011 NASDAQ: QCOR June 2011
Questcor Pharmaceuticals — Investor Presentation (June 2011) on 6ix